Omadacycline tosylate - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for omadacycline tosylate and what is the scope of freedom to operate?
Omadacycline tosylate
is the generic ingredient in one branded drug marketed by Paratek Pharms Inc and is included in two NDAs. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.Omadacycline tosylate has two hundred and forty-five patent family members in forty countries.
One supplier is listed for this compound.
Summary for omadacycline tosylate
| International Patents: | 245 |
| US Patents: | 10 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 12 |
| DailyMed Link: | omadacycline tosylate at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for omadacycline tosylate
Generic Entry Dates for omadacycline tosylate*:
Constraining patent/regulatory exclusivity:
GENERATING ANTIBIOTIC INCENTIVES NOW Dosage:
POWDER;INTRAVENOUS |
Generic Entry Dates for omadacycline tosylate*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for omadacycline tosylate
| Drug Class | Tetracycline-class Antibacterial |
US Patents and Regulatory Information for omadacycline tosylate
Expired US Patents for omadacycline tosylate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Paratek Pharms Inc | NUZYRA | omadacycline tosylate | POWDER;INTRAVENOUS | 209817-001 | Oct 2, 2018 | ⤷ Try a Trial | ⤷ Try a Trial |
| Paratek Pharms Inc | NUZYRA | omadacycline tosylate | TABLET;ORAL | 209816-001 | Oct 2, 2018 | ⤷ Try a Trial | ⤷ Try a Trial |
| Paratek Pharms Inc | NUZYRA | omadacycline tosylate | TABLET;ORAL | 209816-001 | Oct 2, 2018 | ⤷ Try a Trial | ⤷ Try a Trial |
| Paratek Pharms Inc | NUZYRA | omadacycline tosylate | POWDER;INTRAVENOUS | 209817-001 | Oct 2, 2018 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for omadacycline tosylate
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Ecuador | SP10010576 | FORMULACIONES ORALES E INYECTABLES DE COMPUESTOS DE TETRACICLINA | ⤷ Try a Trial |
| Russian Federation | 2010144130 | ПЕРОРАЛЬНАЯ И ИНЪЕКЦИОННАЯ КОМПОЗИЦИИ 9-[(2,2-ДИМЕТИЛПРОПИЛАМИНО)МЕТИЛ]МИНОЦИКЛИНА И СПОСОБ ПОЛУЧЕНИЯ ПЕРОРАЛЬНОЙ КОМПОЗИЦИИ | ⤷ Try a Trial |
| Japan | 2009029785 | 9-SUBSTITUTED MINOCYCLINE COMPOUND | ⤷ Try a Trial |
| Brazil | PI0909211 | formulação orais e injetáveis de composto de tetraciclina | ⤷ Try a Trial |
| Canada | 2717703 | COMPOSES DE MINOCYCLINE ET PROCEDES D'UTILISATION DE CEUX-CI (MINOCYCLINE COMPOUNDS AND METHODS OF USE THEREOF) | ⤷ Try a Trial |
| South Korea | 101093842 | ⤷ Try a Trial | |
| Brazil | 112019001948 | método de tratamento de um indivíduo humano. | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2023 - 2024
NCE-1 Patent Challenge Dates 2023 - 2024
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2023, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
